вторник, 28 февраля 2017 г.

Valeant Q4 loss loss grows, sales fall 13% but adjusted earnings above estimates

Valeant Q4 loss loss grows, sales fall 13% but adjusted earnings above estimates


Valeant Pharmaceuticals International Inc says its fourth quarter loss grew to US$515 million as the drug company's revenue fell 13 per cent compared with the same period in 2015. The Montreal-area company's net loss, reported in U.S. currency, was equal to $1.47 per share while revenue was $2.4 billion, down $355 million from a year earlier.



from Biotech News